Use of multimodality imaging, histology, and treatment feasibility to characterize a transgenic Rag2-null rat model of glioblastoma

• Published in: Frontiers in oncology Vol. 12; p. 939260
• Main Authors: Jackson, Luke R., Masi, Megan R., Selman, Bryce M., Sandusky, George E., Zarrinmayeh, Hamideh, Das, Sudip K., Maharjan, Surendra, Wang, Nian, Zheng, Qi-Huang, Pollok, Karen E., Snyder, Scott E., Sun, Phillip Zhe, Hutchins, Gary D., Butch, Elizabeth R., Veronesi, Michael C.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.11.2022
• Subjects: amino acid PET; CEST MRI; glioblastoma; hybrid PET/MRI; magnetic resonance imaging (MRI); Oncology; positron emission tomography (PET); magnetic resonance imaging (MRI); glioblastoma; positron emission tomography (PET); hybrid PET/MRI; CEST MRI; amino acid PET; amide proton transfer (APT) imaging

Many drugs that show potential in animal models of glioblastoma (GBM) fail to translate to the clinic, contributing to a paucity of new therapeutic options. In addition, animal model development often includes histologic assessment, but multiparametric/multimodality imaging is rarely included despit...